CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Dilated cardiomyopathy: so many cardiomyopathies! Sex- and Race-Related Differences in Characteristics and Outcomes of Hospitalizations for Heart Failure With Preserved Ejection Fraction Heart Failure and Atrial Fibrillation, Like Fire and Fury Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

Original Research2020 Dec 10;S1936-878X(20)31001-9.

JOURNAL:JACC Cardiovasc Imaging. Article Link

Impact of Myocardial Scar on Prognostic Implication of Secondary Mitral Regurgitation in Heart Failure

B Tayal, D Debs, F Nabi et al. Keywords: myocardial scar; cardiovascular magnetic resonance; secondary MR; mitral regurgitation volume; mitral regurgitation fraction; HF; LV

Full Text PDF